Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glepaglutide in Short Bowel Syndrome (EASE SBS 3)
NCT04881825Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Jun 2021
- Primary completion
- Apr 2026
- Modality
- Peptides
- Countries
- 8
01
Overview
A Phase 3 trial of glepaglutide in short bowel syndrome (SBS), sponsored by Zealand Pharma. Started Jun 2021; status: completed.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT04881825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04881825.